These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 32366854)
1. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Majeed M; Majeed S; Nagabhushanam K; Lawrence L; Mundkur L Sci Rep; 2020 May; 10(1):7440. PubMed ID: 32366854 [TBL] [Abstract][Full Text] [Related]
2. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse. Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120 [TBL] [Abstract][Full Text] [Related]
3. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126 [TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606 [TBL] [Abstract][Full Text] [Related]
6. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH). Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867 [TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932 [TBL] [Abstract][Full Text] [Related]
10. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695 [TBL] [Abstract][Full Text] [Related]
11. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638 [TBL] [Abstract][Full Text] [Related]
12. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Kubota N; Kado S; Kano M; Masuoka N; Nagata Y; Kobayashi T; Miyazaki K; Ishikawa F Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):422-30. PubMed ID: 23611112 [TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Ding Y; Sun X; Chen Y; Deng Y; Qian K Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348 [TBL] [Abstract][Full Text] [Related]
15. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH). Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798 [TBL] [Abstract][Full Text] [Related]
16. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475 [TBL] [Abstract][Full Text] [Related]